| Effect of Oral Cimetidine in the Protoporphyrias (NCT05020184) | Amy K. Dickey, M.D. | 2022-06-14 |
| Light Exposure Patterns and Symptoms Among Patients With Erythropoietic Protoporphyria (NCT03682731) | Bispebjerg Hospital | 2017-04-01 |
| Oral Iron for Erythropoietic Protoporphyrias (NCT02979249) | Icahn School of Medicine at Mount Sinai | 2016-12-01 |
| Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact (NCT01688895) | Icahn School of Medicine at Mount Sinai | 2012-07-01 |
| Phase III Confirmatory Study in Erythropoietic Protoporphyria (NCT01605136) | Clinuvel Pharmaceuticals Limited | 2012-05-01 |
| A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP) (NCT04578496) | Clinuvel Pharmaceuticals Limited | 2011-07-11 |
| Sorbent Therapy of the Cutaneous Porphyrias (NCT01422915) | Brigham and Women's Hospital | 2011-05-01 |
| Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP) (NCT01097044) | Clinuvel Pharmaceuticals Limited | 2010-04-01 |
| Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP) (NCT00979745) | Clinuvel Pharmaceuticals Limited | 2009-09-01 |
| Multicentre Phase III Erythropoietic Protoporphyria Study (NCT04053270) | Clinuvel Pharmaceuticals Limited | 2007-05-01 |
| Does Exercise and Heat Increase the Lightsensibility in Patients With Erythropoietic Protoporphyria (NCT00206869) | Bispebjerg Hospital | 2003-01-01 |
| Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria (NCT00004831) | FDA Office of Orphan Products Development | 1996-10-01 |
| Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria (NCT00004940) | Brigham and Women's Hospital | 1996-05-01 |